Emmaus Life Sciences, Inc.
EMMA
$0.0115
-$0.0024-17.27%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -29.92% | -34.70% | -43.73% | -28.22% | -29.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -29.92% | -34.70% | -43.73% | -28.22% | -29.64% |
| Cost of Revenue | 19.38% | -0.09% | -10.51% | -39.70% | -57.45% |
| Gross Profit | -32.26% | -36.38% | -45.31% | -27.45% | -27.40% |
| SG&A Expenses | -28.61% | -29.64% | -29.06% | -23.43% | -23.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.32% | -28.64% | -28.82% | -26.30% | -26.68% |
| Operating Income | -39.41% | -106.82% | -153.50% | -97.65% | -1,038.55% |
| Income Before Tax | 25.24% | 7.38% | -69.41% | 23.28% | -1.96% |
| Income Tax Expenses | -1,062.00% | 134.78% | 149.15% | -228.99% | -1,150.00% |
| Earnings from Continuing Operations | 35.58% | 4.21% | -72.86% | 26.28% | -1.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.58% | 4.21% | -72.86% | 26.28% | -1.08% |
| EBIT | -39.41% | -106.82% | -153.50% | -97.65% | -1,038.55% |
| EBITDA | -41.70% | -105.67% | -152.41% | -94.91% | -697.62% |
| EPS Basic | 35.01% | 9.00% | -39.06% | 41.23% | 19.51% |
| Normalized Basic EPS | 18.68% | 22.15% | -104.12% | 14.99% | 12.13% |
| EPS Diluted | 13.18% | -12.64% | -58.39% | 18.58% | 16.51% |
| Normalized Diluted EPS | 6.29% | 9.25% | -103.81% | 2.40% | 2.05% |
| Average Basic Shares Outstanding | 9.16% | 14.06% | 19.09% | 18.12% | 15.45% |
| Average Diluted Shares Outstanding | 11.16% | 14.78% | 18.40% | 17.70% | 57.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |